Citigroup
PCVX icon

Citigroup’s Vaxcyte PCVX Stock Holding History

Citigroup’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Buy
202,673
+70,495
+53% +$3.83M ﹤0.01% 1488
2026
Q1 		$7.68M Sell
132,178
-109,702
-45% -$5.96M ﹤0.01% 1635
2025
Q4 		$11.2M Sell
241,880
-71,198
-23% -$3.18M ﹤0.01% 1451
2025
Q3 		$11.3M Sell
313,078
-116,206
-27% -$3.85M 0.01% 1398
2025
Q2 		$14M Sell
429,284
-191,795
-31% -$6.29M 0.01% 1175
2025
Q1 		$23.5M Buy
621,079
+241,871
+64% +$19.3M 0.01% 882
2024
Q4 		$31M Buy
379,208
+158,665
+72% +$15.8M 0.02% 730
2024
Q3 		$25.2M Buy
220,543
+54,748
+33% +$4.93M 0.01% 835
2024
Q2 		$12.5M Buy
165,795
+20,928
+14% +$1.42M 0.01% 1131
2024
Q1 		$9.9M Buy
144,867
+65,955
+84% +$4.57M 0.01% 1256
2023
Q4 		$4.96M Sell
78,912
-16,527
-17% -$858K ﹤0.01% 1601
2023
Q3 		$4.87M Buy
95,439
+16,816
+21% +$830K ﹤0.01% 1446
2023
Q2 		$3.93M Sell
78,623
-69,463
-47% -$3.29M ﹤0.01% 1657
2023
Q1 		$5.55M Buy
148,086
+29,320
+25% +$1.24M ﹤0.01% 1452
2022
Q4 		$5.69M Sell
118,766
-36,673
-24% -$1.44M ﹤0.01% 1405
2022
Q3 		$3.73M Buy
155,439
+99,373
+177% +$2.52M ﹤0.01% 1717
2022
Q2 		$1.22M Buy
56,066
+43,686
+353% +$1.01M ﹤0.01% 2482
2022
Q1 		$299K Sell
12,380
-34,053
-73% -$744K ﹤0.01% 3842
2021
Q4 		$1.1M Buy
46,433
+21,159
+84% +$492K ﹤0.01% 3141
2021
Q3 		$641K Sell
25,274
-59,741
-70% -$1.45M ﹤0.01% 3441
2021
Q2 		$1.91M Sell
85,015
-28,311
-25% -$580K ﹤0.01% 2697
2021
Q1 		$2.24M Buy
113,326
+108,056
+2,050% +$2.72M ﹤0.01% 2416
2020
Q4 		$140K Buy
5,270
+4,396
+503% +$163K ﹤0.01% 5258
2020
Q3 		$43K Buy
+874
New +$34.8K ﹤0.01% 5694

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citigroup's PCVX Position: Q2 2026 in Review

Citigroup increased its Vaxcyte (PCVX) stake by 53% in Q2 2026, buying an estimated $3.83M and bringing the position to 202,673 shares worth $11.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

Citigroup first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $31M in Q4 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Citigroup held 202,673 shares of Vaxcyte worth $11.8M as of Q2 2026.
  • Citigroup bought 70,495 Vaxcyte shares in Q2 2026, an estimated $3.83M.
  • Vaxcyte made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1488 holding.
  • Citigroup first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • Citigroup's Vaxcyte position peaked at $31M in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.